Boston Scientific stock: TD Cowen keeps USD 56.00 target for Boston Scientific stock

Published on 10/21/2026 at 17:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific reports on October 28, 2026, before the open. Boston Scientific stock costs EUR 39.31 on October 21, 2026 at 5:36 p.m. CEST.

Analyst and reporting date

TD Cowen reiterated a Buy rating and set a USD 56.00 target on October 20, 2026.
Boston Scientific is scheduled to report third-quarter results on October 28, 2026.
Boston Scientific stock costs EUR 39.31 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST.

Architektonisches 3D-Render eines geschwungenen Glas-Bürohochhauses mit Wasserspiegelanlage — Boston Properties US1011371077 präsentiert ein zeitgenössisches Architektur-Render eines Hochhauses mit urbanem Wasserspiegelplatz, Illustration mit AI erstellt.

Boston Scientific Corporation (ISIN US1011371077) has a USD 56.00 price target from TD Cowen, which reiterated its Buy rating on October 20, 2026. The target stands 26.93 percent above the NYSE price of USD 44.12 at the time of the analyst note, based on Investing.com. Boston Scientific stock was trading at EUR 39.31 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST.

Results date sets the next test

Boston Scientific is scheduled to report third-quarter results before the open on October 28, 2026, according to Gekko. The date gives investors a defined checkpoint for the medical-device maker after recent analyst attention centered on the 2027 outlook and near-term operating pressure.

Stock sits near its yearly low

On the NYSE, Boston Scientific was last at USD 44.12 on October 21, 2026 at 11:37 a.m. EDT. The same session data placed the stock within a 52-week range of USD 41.39 to USD 105.65, leaving the price 6.59 percent above the low and 58.20 percent below the high.

The valuation also shows a wide gap between Boston Scientific and its larger medical-device peers. Boston Scientific had a price-to-earnings ratio of 17.93 and a market capitalization of USD 63.9 billion on October 21, 2026. Abbott Laboratories stood at a price-to-earnings ratio of 31.57 and a market capitalization of USD 170.0 billion, while Danaher had a ratio of 38.16 and a market capitalization of USD 164.1 billion on the same date.

What does the target imply?

TD Cowen's USD 56.00 target implies 26.93 percent upside from the USD 44.12 NYSE price cited in the October 20, 2026 report. That comparison is separate from the euro quotation used for German investors, because the target and home-market price are denominated in USD.

Boston Scientific's latest reported quarter ended June 30, 2026. MarketBeat reported adjusted earnings per share of USD 0.86 for that quarter and full-year 2026 adjusted earnings-per-share guidance of USD 3.28 to USD 3.32. The figures provide the operating backdrop for the October 28 report without changing the analyst target.

Price and investor perspective

The key question for the next report is whether Boston Scientific can support the longer-term 2027 view while the stock remains near its 52-week low. For German investors, the euro quote remains the cleanest live trading reference, while the USD figures show how analysts and the home market value the company.

Boston Scientific was trading at EUR 39.31 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.